Ispire Technology price target lowered to $7.50 from $9 at Roth Capital

Roth Capital lowered the firm’s price target on Ispire Technology (ISPR) to $7.50 from $9 and keeps a Buy rating on the shares. The company’s Q2 results were “tempered” as shipment timing on its U.K. supply agreement is being pushed into fiscal Q4 and given that Chinese New Year seasonality and tariffs are also impacting order timing, the analyst tells investors in a research note. An FDA decision in the coming months should provide greater future visibility around licensing opportunities, the firm adds.